PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1127.90
Negative P/E while Drug Manufacturers - Specialty & Generic median is 2.24. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
234.74
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.87. Jim Chanos would check for potential asset write-down risks.
-20482.07
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -10.78. Seth Klarman would investigate cash flow improvement potential.
-20482.07
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
234.74
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.89. Jim Chanos would check for valuation bubble risks.
-0.02%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is 0.32%. Seth Klarman would investigate path to profitability.
-0.00%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.05%. Seth Klarman would investigate cash flow improvement potential.